Transdermal Drug Delivery Market 2017-2023
- November, 2017
- Domain: Healthcare - Pharmaceuticals
- Get Free 10% Customization in this Report
Transdermal drug delivery system (TDDS) is an independent, distinct dosage form of drug applied to intact skin to deliver the drug at a meticulous rate to the blood. The transdermal route of governing the drugs is known to be one of the budding route for indigenous and systemic drug delivery process.
The first transdermal drug delivery system, Transderm-SCOP received US FDA approval in the year 1979 for the stoppage of nausea and vomiting. Since then the technology has greatly developed. The first-generation transdermal drug delivery majorly involved delivery of small, lipophilic, and uncharged molecules by passive diffusion technology. Maximum products that are currently available in the market belong to this generation. However, development of technology has led to the use of chemical enhancers and other energy-based techniques such as ultrasound to enhance the permeation of the drug through the skin. They belong to the second generation of transdermal products. The delivery of lidocaine is done by an iontophoretic delivery system, which was developed and marketed during this generation. A third generation of delivery systems are the ones that are currently under development including microneedles and electroporation to deliver macromolecules.
The “Global Transdermal Drug Delivery Market” is estimated to witness a CAGR of 9.5% during the forecast period 2017–2023. The Transdermal Drug Delivery market is analyzed based on four segments – Product Type, Technology, Drug Type, and Regions.
The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). In the North American region, the US is set to be the leading country. The Europe is set to be the second leading region and holds more than 26.3% of the market share in 2016. In Asia Pacific, India, Japan, and China is one of the most attractive countries for the players and holds huge business opportunities. RoW is set to be an emerging market in the next 5-6 years.
Based on the technology types, the market is segmented into Passive and Active transdermal technology. At present the market is dominated by passive technology. However, the advent of novel technology for enhancing the permeation of drugs through skin the skin is driving the market growth. Hence the highest growth rate is expected to be in witnessed in the active transdermal drug delivery technology.
Product Types Analysis
The product types covered in the report are Patches and Gels. Transdermal Patches are likely to continue to dominate the market by 2023. Stringent regulatory approval and high cost of the transdermal drug delivery systems represents as the major challenge the growth of transdermal drug delivery market. The market is expected to be on a positive year on year growth rate, as the increase in chronic diseases prevalence and expanded application areas of the technology is expected during the forecast period.
3M, Boehringer Ingelheim, Johnson and Johnson, Mylan N.V., Novartis, and GlaxoSmithKline, are the key players in the market. Echo Therapeutics Inc., Noven Pharmaceuticals, Transdermal Corp, Actavis, Bayer, and Corium International, are the other key players in the market.
The transdermal drug delivery market is highly lucrative. Many players are developing advanced technology products and if involved in expanding the application areas of these drug delivery systems. In 2017, Nemaura Pharma, a UK-based company has developed Memspatch, to increase the penetration rate of gel by three-times faster than the ones that are already available in the market. Apart from this the major players in the market are collaborating with other major players in the market. For instance, In January 2017, 3M Drug Delivery Systems entered into collaboration with Panacea Pharmaceuticals, Inc. to deliver a new therapeutic cancer vaccine directly to the dermis through the 3M Hollow Microstructure Transdermal System (hMTS).
The report provides complete details about the usage and adoption rate of transdermal drug delivery in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.
1 Industry Outlook
1.1 Industry Overview
1.2 Industry Trends
1.3 Total Addressable Market
2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 Market Snapshot
3.1 Market Definition – Infoholic Research
3.2 Segmented Addressable Market
3.2.1 Components of Transdermal Patch
3.2.2 Advantages of Transdermal Drug Delivery
3.2.3 Disadvantages of Transdermal Drug Delivery
3.2.4 Diseases Treated by Transdermal Drug Delivery Systems
3.2.5 Trends in Transdermal Drug Delivery Market
3.3 Related Markets
3.3.1 Active Pharmaceutical Ingredients
3.3.2 Pulmonary Drug Delivery Systems
3.3.3 Injectable Drug Delivery Systems
4 Market Outlook
4.2 Market Segmentation
4.3 Porter 5(Five) Forces
4.4 PEST Analysis
5 Market Characteristics
5.1 Market Dynamics
188.8.131.52 Increasing aging population
184.108.40.206 Growing patient base of chronic diseases
220.127.116.11 Increasing demand for transdermal drug delivery
18.104.22.168 Increased healthcare spending
22.214.171.124 Increasing clinical trials and product launches
126.96.36.199 Side effects of transdermal drug delivery
188.8.131.52 Delivery limitation through skin
184.108.40.206 Availability of alternative drug delivery systems
5.2 DRO – Impact Analysis
5.3 Key Stakeholders
6 Types: Market Size and Analysis
7 Technology: Market Size and Analysis
7.3.1 Thermal Technology
7.3.2 Ultrasound Devices
7.3.3 Electrical Techniques
7.3.4 Mechanical Methods
7.3.5 Velocity-based Devices
8 Drug Types: Market Size and Analysis
8.3 Nicotine Transdermal Patch
8.4 Nitroglycerin Transdermal Patch
8.5 Clonidine Transdermal Patch
9 Regions: Market Size and Analysis
9.2 North America
9.4 Asia Pacific
9.5 Rest of the World
10 Competitive Landscape
11 Vendor Profiles
11.1 Novartis AG
11.1.2 Business Units
11.1.3 Geographic Revenue
11.1.4 Business Focus
11.1.5 SWOT Analysis
11.1.6 Business Strategies
11.2.2 Business Units
11.2.3 Geographic Revenue
11.2.4 Business Focus
11.2.5 SWOT Analysis
11.2.6 Business Strategies
11.3 Johnson & Johnson (Janssen Pharmaceuticals Inc.)
11.3.2 Business Units
11.3.3 Geographic Revenue
11.3.4 Business Focus
11.3.5 SWOT Analysis
11.3.6 Business Strategies
11.4 GlaxoSmithKline plc
11.4.2 Business Units
11.4.3 Geographic Revenue
11.4.4 Business Focus
11.4.5 SWOT Analysis
11.4.6 Business Strategies
11.5 Boehringer Ingelheim GmbH
11.5.2 Business Units
11.5.3 Geographic Revenue
11.5.4 Business Focus
11.5.5 SWOT Analysis
11.5.6 Business Strategies
11.6 Mylan N.V.
11.6.2 Business Units
11.6.3 Geographic Revenue
11.6.4 Business Focus
11.6.5 SWOT Analysis
11.6.6 Business Strategies
12 Companies to Watch For
12.1 Echo Therapeutics, Inc.
12.2 Noven Pharmaceuticals, Inc.
12.3 Transdermal Corp.
12.4 Bayer AG
12.5 Actavis, Inc.
12.6 Corium International, Inc.
TABLE 1 TRANSDERMAL DRUG DELIVERY MARKET REVENUE BY REGIONS, 2016–2023 ($MILLION) 36
TABLE 2 PROMINENT VENDORS IN THE MARKET 42
TABLE 3 NOVARTIS AG: OFFERINGS 45
TABLE 4 NOVARTIS AG: RECENT DEVELOPMENTS 45
TABLE 5 3M: OFFERINGS 51
TABLE 6 3M: RECENT DEVELOPMENTS 51
TABLE 7 JOHNSON & JOHNSON: PRODUCT OFFERINGS 56
TABLE 8 JOHNSON & JOHNSON: RECENT DEVELOPMENTS 56
TABLE 9 GLAXOSMITHKLINE PLC: OFFERINGS 63
TABLE 10 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS 64
TABLE 11 BOEHRINGER INGELHEIM GMBH: OFFERINGS 69
TABLE 12 BOEHRINGER INGELHEIM GMBH: RECENT DEVELOPMENTS 69
TABLE 13 MYLAN N.V.: OFFERINGS 74
TABLE 14 MYLAN N.V.: RECENT DEVELOPMENTS 74
TABLE 15 ECHO THERAPEUTICS, INC.: OVERVIEW 79
TABLE 16 NOVEN PHARMACEUTICALS, INC.: OVERVIEW 79
TABLE 17 TRANSDERMAL CORP.: OVERVIEW 80
TABLE 18 BAYER AG: OVERVIEW 81
TABLE 19 BAYER AG: RECENT DEVELOPMENTS 81
TABLE 20 ACTAVIS, INC.: OVERVIEW 82
TABLE 21 CORIUM INTERNATIONAL, INC.: OVERVIEW 82
TABLE 22 CORIUM INTERNATIONAL, INC.: RECENT DEVELOPMENTS 83
Infoholic Research works on a holistic 360° approach in order to deliver high quality, validated and reliable information in our market reports. The Market estimation and forecasting involves following steps:
- Data Collation (Primary & Secondary)
- In-house Estimation (Based on proprietary data bases and Models)
- Market Triangulation
Market related information is congregated from both primary and secondary sources.
Involved participants from all global stakeholders such as Solution providers, service providers, Industry associations, thought leaders etc. across levels such as CXOs, VPs and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.
Include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications along with paid sources such as Factiva, OneSource, Bloomberg among others.